Graves OphthalmopathyDrugEarly Phase 1
What this study is
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
What's being tested
- Bimatoprost Ophthalmic
Intervention · DRUG
Bimatoprost, aka Lumigan, one drop in one eye nightly
Study details
- Official title
- The Role of Bimatoprost in Graves' Periorbitopathy
- Sponsor
- Johns Hopkins University
- Conditions
- Graves Ophthalmopathy
- Enrolling
- 3 people
- Starts
- 2017-11-01
- Est. completion
- 2031-07-01
- Design
- Single-blind, non-randomized, parallel groups, Early Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Graves' Ophthalmopathy with Exophthalmos/Proptosis -
You can't join if
- Active Graves Disease, Currently pregnant, Taking Steroids
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Washington
Seattle, Washington, United States
- Alexandra Van Brummen, MD · Contact206-543-7250avanbrum@uw.edu
Recruiting
Study team
Sponsor
Johns Hopkins University
Study ID IRB00294393
Principal investigator
Emily Li, MD
Johns Hopkins University
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.